Kite Pharma Names Christine Cassiano as Senior Vice President of Corporate Communications and Investor Relations
Christine Cassiano as Senior Vice President of Corporate Communications and Investor Relations. She will also sit on the company's Executive Committee. In this new position, Cassiano will be responsible for transforming Kite's communications function to keep pace with the company's expanding pipeline of chimeric antigen receptor (CAR) and T-cell receptor (TCR) product candidates to treat both hematological (blood-based) and solid cancers.
Christine Cassiano, SVP,
"Christine arrives at a key inflection point for Kite as we advance our
CAR-T and TCR pipeline toward key company milestones, including our BLA
submission for KTE-C19 with the
Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer of Kite. "Christine's progressive communications approach and vast experience will allow us to enhance our education of key audiences on the changing cancer treatment paradigm, the value of CAR-T therapy, and our role in its innovation."
With a dual background in investor and public relations, Christine has an extensive history developing innovative approaches that advance communications in corporate positioning, issues management, employee engagement, commercialization and investor relations.
"My enthusiasm for Kite's groundbreaking research goes beyond my professional drive to innovate healthcare communications - it is also deeply personal," said Cassiano. "Like many who have lost a loved one to cancer, I understand first-hand the optimism and promise scientific progress offers to patients whose lives depend on significant breakthroughs in care. I am eager to further the understanding of Kite's role in advancing breakthrough therapies for cancer."
Cassiano was most recently Head of Healthcare for the
About Kite Pharma
This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. The press release may, in some cases, use terms such as
"predicts," "believes," "potential," "proposed," "continue,"
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should" or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding intentions, beliefs, projections, outlook, analyses
or current expectations concerning, among other things: submitting a
Biologics License Application (BLA) for KTE-C19 with the